All In MedTech

Device Trial Radar · NCT06895785

Exalt Single-use Duodenoscope Vs Reusable Scope, a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 21, 2025

Primary completion

Feb 2030

Study completion May 2030

Sponsor

Lead sponsor
Rush University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 26, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial (RCT) is designed to evaluate the new generation Exalt Model disposable duodenoscope compared to the reusable scope in terms of feasibility, ease of use, adverse events, number of crossover events, and infection rates.

Conditions

  • Biliary Diseases
  • Pancreatic Duct Disorder

Interventions

  • Exalt Model DDevice

    Exalt Model D single-use duodenoscope will be used in ERCP

  • ReusableDevice

    Standard reusable duodenoscope will be used in ERCP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of attempts required to achieve successful cannulation of the desired ductTime frame: From the time of the ERCP to 7 days post-ERCP per standard of care

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.